Elsulfavirine: First Global Approval
Elsulfavirine: First Global Approval
复制标题
DOI：
10.1007/s40265-017-0820-3
复制
发表时间：
2017-10-01
期刊：
影响因子：
11.5
通讯作者：
Al-Salama, Zaina T.
中科院分区：
文献类型：
--
作者：
Al-Salama, Zaina T.
Elsulfavirine（Elpida（R））是Viriom开发的新一代非核苷逆转录酶抑制剂（NNRTI），用于治疗和预防人类免疫缺陷病毒（HIV）感染。它是活性化合物VM-1500 A的前药，VM-1500 A是一种小分子选择性NNRTI，可防止HIV复制。2017年6月，elsulfavirine在俄罗斯首次获得全球批准，用于与其他抗逆转录病毒药物联合治疗HIV-1感染。该药物的其他制剂也正在临床前和II期研究中进行评估，用于治疗艾滋病毒感染和/或暴露前和暴露后预防。本文总结了艾舒法韦林开发过程中的里程碑，导致其首次获得批准用于HIV-1治疗。
Elsulfavirine (Elpida (R)) is a new-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Viriom for the treatment and prevention of human immunodeficiency virus (HIV) infections. It is the prodrug of the active compound VM-1500A, a small molecule selective NNRTI, which prevents HIV replication. In June 2017, elsulfavirine received its first global approval in Russia for the treatment of HIV-1 infections in combination with other antiretroviral medicines. Other formulations of this drug are also being evaluated in preclinical and phase II studies for the treatment of HIV infections and/or pre-exposure and post-exposure prophylaxis. This article summarizes the milestones in the development of elsulfavirine leading to this first approval in HIV-1 treatment.